Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aniracetam→

Aniracetam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
72432-10-1
Molecular formula
C12H13NO3
Molecular weight
219.24 g/mol
Drug class
Racetam nootropicpositive allosteric modulator of AMPA-type glutamate receptors
Mechanism of action
Has been reported to modulate AMPA-type glutamate receptor activity and influence cholinergic, dopaminergic and serotonergic neurotransmission. Its mechanisms in humans and clinical relevance remain incompletely established.
Indications / reported uses
  • Investigational or non-approved nootropic use in some markets; aniracetam does not have a broadly recognised major-market marketing authorisation for a defined therapeutic indication.

Sources: https://pubmed.ncbi.nlm.nih.gov/?term=aniracetam+AMPA+receptor+mechanism · https://pubchem.ncbi.nlm.nih.gov/#query=aniracetam

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aniracetam Environmental Risk Assessment (ERA) (the Aniracetam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.